Cancer Research Annual Meeting 2010 Telomeres
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Lupold, S. E.
Right arrow Articles by Coffey, D. S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Lupold, S. E.
Right arrow Articles by Coffey, D. S.
[Cancer Research 62, 4029-4033, July 15, 2002]
© 2002 American Association for Cancer Research

Experimental Therapeutics

Identification and Characterization of Nuclease-stabilized RNA Molecules That Bind Human Prostate Cancer Cells via the Prostate-specific Membrane Antigen1

Shawn E. Lupold2, Brian J. Hicke3, Yun Lin and Donald S. Coffey

Department of Urology, Johns Hopkins University School of Medicine, Baltimore, Maryland 21287-2101 [S. E. L., D. S. C.], and Gilead Sciences, Boulder, Colorado 80301 [B. J. H., Y. L.].

We have identified two synthetic oligonucleotides (aptamers) that bind to prostate cancer cells,with low nanomolar affinity, via the extracellular portion of the prostate-specificmembrane antigen (PSMA). These two specific aptamers were selected from an initial 40mer library of ~6 x 1014 random-sequence RNA molecules for their ability to bind to a recombinant protein representing the extracellular 706 amino acids of PSMA, termed xPSM. Six rounds of in vitro selection were performed, enriching for xPSM binding as monitored by aptamer inhibition of xPSM N-acetyl-{alpha}-linked acid dipeptidase (NAALADase) enzymatic activity. By round six, 95% of the aptamer pool consisted of just two sequences. These two aptamers, termed xPSM-A9 and xPSM-A10, were cloned and found to be unique, sharing no consensus sequences. The affinity of each aptamer for PSMA was quantitated by its ability to inhibit NAALADase activity. Aptamer xPSM-A9 inhibits PSMA noncompetitively with an average Ki of 2.1 nM, whereas aptamer xPSM-A10 inhibits competitively with an average Ki of 11.9 nM. Distinct modes of inhibition suggest that each aptamer identifies a unique extracellular epitope of xPSM. One aptamer was truncated from 23.4 kDa to 18.5 kDa and specifically binds LNCaP human prostate cancer cells expressing PSMA but not PSMA-devoid PC-3 human prostate cancer cells. These are the first reported RNA aptamers selected to bind a tumor-associated membrane antigen and the first application of RNA aptamers to a prostate specific cell marker. These aptamers may be used clinically as NAALADase inhibitors or be modified to carry imaging agents and therapeutic agents directed to prostate cancer cells.




This article has been cited by other articles:


Home page
 J BiochemHome page
T. Shishido, Y. Azumi, T. Nakanishi, M. Umetsu, T. Tanaka, C. Ogino, H. Fukuda, and A. Kondo
Biotinylated Bionanocapsules for Displaying Diverse Ligands Toward Cell-specific Delivery
J. Biochem., December 1, 2009; 146(6): 867 - 874.
[Abstract] [Full Text] [PDF]

Home page
 Nucleic Acids ResHome page
J. Zhou, P. Swiderski, H. Li, J. Zhang, C. P. Neff, R. Akkina, and J. J. Rossi
Selection, characterization and application of new RNA HIV gp 120 aptamers for facile delivery of Dicer substrate siRNAs into HIV infected cells
Nucleic Acids Res., May 1, 2009; 37(9): 3094 - 3109.
[Abstract] [Full Text] [PDF]

Home page
 Proc. Natl. Acad. Sci. USAHome page
S. Dhar, F. X. Gu, R. Langer, O. C. Farokhzad, and S. J. Lippard
Targeted delivery of cisplatin to prostate cancer cells by aptamer functionalized Pt(IV) prodrug-PLGA-PEG nanoparticles
PNAS, November 11, 2008; 105(45): 17356 - 17361.
[Abstract] [Full Text] [PDF]

Home page
 Proc. Natl. Acad. Sci. USAHome page
F. Gu, L. Zhang, B. A. Teply, N. Mann, A. Wang, A. F. Radovic-Moreno, R. Langer, and O. C. Farokhzad
From the Cover: Precise engineering of targeted nanoparticles by using self-assembled biointegrated block copolymers
PNAS, February 19, 2008; 105(7): 2586 - 2591.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
K. Rege, S. J. Patel, Z. Megeed, and M. L. Yarmush
Amphipathic Peptide-Based Fusion Peptides and Immunoconjugates for the Targeted Ablation of Prostate Cancer Cells
Cancer Res., July 1, 2007; 67(13): 6368 - 6375.
[Abstract] [Full Text] [PDF]

Home page
 aacredbookHome page
A. D. Ellington, J. Ebright, T. Chu, and M. Levy
Using Aptamers for Cell-Specific Labeling and Delivery
Am. Assoc. Cancer Res. Educ. Book, April 14, 2007; 2007(1): 51 - 55.
[Full Text] [PDF]

Home page
 Nucleic Acids ResHome page
Y. Li, H. J. Lee, and R. M. Corn
Fabrication and characterization of RNA aptamer microarrays for the study of protein-aptamer interactions with SPR imaging
Nucleic Acids Res., December 2, 2006; 34(22): 6416 - 6424.
[Abstract] [Full Text] [PDF]

Home page
 JAMAHome page
D. S. Coffey, R. H. Getzenberg, and T. L. DeWeese
Hyperthermic biology and cancer therapies: a hypothesis for the "Lance Armstrong effect".
JAMA, July 26, 2006; 296(4): 445 - 448.
[Full Text] [PDF]

Home page
 Cancer Res.Home page
T. C. Chu, J. W. Marks III, L. A. Lavery, S. Faulkner, M. G. Rosenblum, A. D. Ellington, and M. Levy
Aptamer:Toxin Conjugates that Specifically Target Prostate Tumor Cells.
Cancer Res., June 15, 2006; 66(12): 5989 - 5992.
[Abstract] [Full Text] [PDF]

Home page
 Nucleic Acids ResHome page
T. C. Chu, K. Y. Twu, A. D. Ellington, and M. Levy
Aptamer mediated siRNA delivery
Nucleic Acids Res., June 1, 2006; 34(10): e73 - e73.
[Abstract] [Full Text] [PDF]

Home page
 Proc. Natl. Acad. Sci. USAHome page
O. C. Farokhzad, J. Cheng, B. A. Teply, I. Sherifi, S. Jon, P. W. Kantoff, J. P. Richie, and R. Langer
Targeted nanoparticle-aptamer bioconjugates for cancer chemotherapy in vivo
PNAS, April 18, 2006; 103(16): 6315 - 6320.
[Abstract] [Full Text] [PDF]

Home page
 Nucleic Acids ResHome page
D. A. Di Giusto, W. A. Wlassoff, J. J. Gooding, B. A. Messerle, and G. C. King
Proximity extension of circular DNA aptamers with real-time protein detection
Nucleic Acids Res., April 7, 2005; 33(6): e64 - e64.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
O. C. Farokhzad, S. Jon, A. Khademhosseini, T.-N. T. Tran, D. A. LaVan, and R. Langer
Nanoparticle-Aptamer Bioconjugates: A New Approach for Targeting Prostate Cancer Cells
Cancer Res., November 1, 2004; 64(21): 7668 - 7672.
[Abstract] [Full Text] [PDF]

Home page
 Molecular Cancer TherapeuticsHome page
S. E. Lupold and R. Rodriguez
Disulfide-constrained peptides that bind to the extracellular portion of the prostate-specific membrane antigen
Mol. Cancer Ther., May 1, 2004; 3(5): 597 - 603.
[Abstract] [Full Text] [PDF]

Home page
 Nucleic Acids ResHome page
J. F. Lee, J. R. Hesselberth, L. A. Meyers, and A. D. Ellington
Aptamer Database
Nucleic Acids Res., January 1, 2004; 32(90001): D95 - 100.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 2002 by the American Association for Cancer Research.